170161-27-0

Basic information

• Product Name: 1,4,8-Tri-Boc-1,4,8,11-tetraazacyclotetradecane
• Synonyms: 1,4,8-Tri-Boc-1,4,8,11-tetraazacyclotetradecane;1,4,8,11-Tetraazacyclotetradecane-1,4,8-tricarboxylic acid, tris(1,1-diMethylethyl) ester;tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate
• CAS NO: 170161-27-0
• Molecular Formula: C₂₅H₄₈N₄O₆
• Molecular Weight: 500.67
• Mol File: 170161-27-0.mol
• Article Data: 32

Chemical Properties

• Melting Point: 48-54°C
• Boiling Point: 568.6°C at 760 mmHg
• Flash Point: 297.7°C
• Appearance: /
• Density: 1.09g/cm³
• Vapor Pressure: 6.04E-13mmHg at 25°C
• Refractive Index: 1.511
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 10.01±0.20(Predicted)
• Sensitive: Hygroscopic
• CAS DataBase Reference: 1,4,8-Tri-Boc-1,4,8,11-tetraazacyclotetradecane(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4,8-Tri-Boc-1,4,8,11-tetraazacyclotetradecane(170161-27-0)
• EPA Substance Registry System: 1,4,8-Tri-Boc-1,4,8,11-tetraazacyclotetradecane(170161-27-0)

Safety Data

• Hazardous Substances Data: 170161-27-0(Hazardous Substances Data)

Usage

General Description

1,4,8-Tri-Boc-1,4,8,11-tetraazacyclotetradecane is a chemical compound with the molecular formula C20H38N4O6. It is a cyclic tetra-amine compound with four nitrogen atoms and four carbon atoms in its ring structure. The compound is commonly used as a protecting group in organic synthesis, particularly in peptide chemistry, to protect amine groups from unwanted reactions. The "Boc" in its name refers to the tert-butoxycarbonyl group, which is often used as a protecting group for amines. The compound is typically synthesized through a series of chemical reactions involving the addition of Boc groups to a cyclen ring structure, and it is commonly used as a versatile building block in the synthesis of complex molecules.

InChI:InChI=1/C25H48N4O6/c1-23(2,3)20(30)35-29-16-10-12-26-13-17-27(21(31)33-24(4,5)6)14-11-15-28(18-19-29)22(32)34-25(7,8)9/h26H,10-19H2,1-9H3

Upstream product

• 295-37-4 1,4,8,11-Tetraazacyclotetradecane 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 175854-46-3 1,1'-m-xylylbis<4,8,11-tris(tert-butyloxycarbonyl)-1,4,8,11-tetraazacyclotetradecane> 
• 321658-93-9 11-(4-chloromethyl-benzoyl)-1,4,8,11tetraaza-cyclotetradecane-1,4,8-tricarboxylic acid tri-tert-butyl ester 
• 850141-57-0 11-(4-nitrobenzyl)-1,4,8-tris-(tert-butoxycarbonyl)-1,4,8,11-tetraazacyclotetradecane 
• 305846-66-6 11-(3-bromomethyl-benzyl)-1,4,8,11tetraaza-cyclotetradecane-1,4,8-tricarboxylic acid tri-tert-butyl ester 
• 957829-81-1 11-(3-benzyloxycarbonylamino-propyl)-1,4,8,11-tetraaza-cyclotetradecane-1,4,8-tricarboxylic acid tri-tert-butyl ester 
• 957829-77-5 11-(2-benzyloxycarbonylamino-acetyl)-1,4,8,11-tetraaza-cyclotetradecane-1,4,8-tricarboxylic acid tri-tert-butyl ester 
• 1242274-98-1 1-[4-(carboxaldehyde)phenylmethyl]-4,8,11-tris-(tert-butoxycarbonyl)-1,4,8,11-tetraazacyclotetradecane 
• 1290538-45-2 11-(2-(4-phenyl-1H-1,2,3-triazol-1-yl)ethyl)-1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylic acid tri-tert-butyl ester 
• 1290538-46-3 1-(2-(4-phenyl-1H-1,2,3-triazol-1-yl)ethyl)-1,4,8,11-tetraazacyclotetradecane 
• 609342-20-3 1-(4-nitrophenyl)-1,4,8,11-tetraaza-cyclotetradecane 

Relevant articles and documents

Structural Differences and Redox Properties of Unsymmetric Diiron PDIxCy Complexes

We present two bimetallic iron complexes, [Fe2(PDIeCy)(OTf)4] (1) and [Fe2(PDIpCy)(THF)(OTf)4] (2) coordinated by an unsymmetric ligand. The new ligand, PDIeCy (PDI = pyridyldiimine; e = ethyl; Cy = cyclam), is

Dual-Function Polymeric HPMA Prodrugs for the Delivery of miRNA

An HPMA-based polymeric prodrug of a CXCR4 antagonist, AMD3465 (P-SS-AMD), was developed as a dual-function carrier of therapeutic miRNA. P-SS-AMD was synthesized by a copolymerization of HPMA with a methacrylamide monomer in which the AMD3465 was attached via a self-immolative disulfide linker. P-SS-AMD showed effective release of the parent AMD3465 drug following treatment with intracellular levels of glutathione (GSH). The AMD3465 was released in the cells and exhibited functional CXCR4 antagonism, demonstrated by inhibition of the CXCR4-mediated cancer cell invasion. Due to its cationic character, P-SS-AMD could form polyplexes with miRNA and mediate efficient transfection of miR-200c mimics to downregulate expression of a downstream target ZEB-1 in cancer cells. The combined P-SS-AMD/miR-200c polyplexes showed improved ability to inhibit cancer cell migration when compared with individual treatments. The reported findings validate P-SS-AMD as a dual-function delivery vector that can simultaneously deliver a therapeutic miRNA and function as a polymeric prodrug of CXCR4 antagonist.

Tri-N-Boc-tetraazamacrocycle-nucleoside conjugates: Synthesis and anti- HIV activities

As far as linear N-Boc-polyamines conjugates elicited remarkable anti- HIV activity, the synthesis and anti-HIV properties of cyclic N-Boc- polyamines conjugates such as tetraazamacro-cycle-nucleoside were studied. These new conjugates include an ester linkage between the two moieties. They were synthesized using Benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate coupling reagent, in the case of N-alkyl polyazamacrocycle derivatives, or through direct condensation of the acyl chloride derivative with nucleoside in the case of Nacyl polyazamacrocycle compounds. None of the new conjugates presented anti-HIV activity greater than that of the corresponding parent nucleosides.

Synthesis and evaluation of [99mTc]TcAMD3465 as a SPECT tracer for CXCR4 receptor imaging

CXCR4 plays an important role in a number of immunological-based diseases and cancers. The development of radiotracers targeting CXCR4 can provide a valuable tool for the diagnosis and monitoring of conditions involving deregulation of the receptor. The i

Synthesis of cyclam-capped β-cyclodextrin-bonded silica particles for use as chiral stationary phases in capillary electrochromatography

β-Cyclodextrin (β-CD) was anchored onto silica particles at its C(2) position, derivatized primarily at the C(6) position by treatment with bromoacetyl bromide, and finally reacted with two types of cyclams to form cyclam-capped β-CD-bonded silica particles. When used as chiral stationary phases in capillary electrochromatography, these novel bonded silica particles exhibited excellent enantioselectivities for chiral separations.

POTENTIATION OF β-LACTAM ANTIBIOTICS AND β-LACTAM/β-LACTAMASE INHIBITOR COMBINATIONS AGAINST MULTIDRUG AND EXTENSIVELY DRUG-RESISTANT PSEUDOMONAS AERUGINOSA USING NON-RIBOSOMAL TOBRAMYCIN-CYCLAM CONJUGATES

Herein, we describe the development of non-β-lactam-based potentiator molecules that synergize with β-lactam antibiotics and β-lactam-β-lactamase inhibitor combinations against MDR/XDR P. aeruginosa phenotypes. The compound comprises a chemical structure